Erik Verner Net Worth

Erik Verner biography

Dr. Erik J. Verner Ph.D. serves as Vice President of Chemistry Research of the Company. Dr. Verner was Director of Chemistry for Principia Biopharma Inc., a biopharmaceutical company. Dr. Verner served as Director of Chemistry of Pharmacyclics, Inc., a biopharmaceutical company, from 2008 to February 2011, where he served as a principal scientist from 2006 to 2008. From 1996 to 2006, Dr. Verner was a principal scientist at Axys Pharmaceuticals, Inc. (formerly Arris Pharmaceuticals, Incorporated), a biotechnology company, and Celera Corporation, a subsidiary of Axys Pharmaceuticals, Inc. He was a senior scientist at Immunopharmaceutics, Inc., a biotechnology company, from 1993 to 1996. Dr. Verner received a B.S. in Chemistry from the University of Idaho and a Ph.D. in Organic Chemistry from the University of Pittsburgh.

How old is Erik Verner?

Erik Verner is 53, he's been the Vice President of Chemistry Research of Corvus Pharmaceuticals Inc since 2015. There are 14 older and 3 younger executives at Corvus Pharmaceuticals Inc. The oldest executive at Corvus Pharmaceuticals Inc is Dr. Richard A. Miller M.D., 70, who is the Co-Founder, Pres, CEO & Chairman.

What's Erik Verner's mailing address?

Erik's mailing address filed with the SEC is C/O CORVUS PHARMACEUTICALS, INC., 863 MITTEN ROAD, SUITE 102, BURLINGAME, CA, 94010.

Insiders trading at Corvus Pharmaceuticals Inc

Over the last 9 years, insiders at Corvus Pharmaceuticals Inc have traded over $52,808,904 worth of Corvus Pharmaceuticals Inc stock and bought 11,523,300 units worth $85,214,510 . The most active insiders traders include Holdings A/S Novo, Street Partners Llc Adams, and Capital, Llc Eco R1. On average, Corvus Pharmaceuticals Inc executives and independent directors trade stock every 46 days with the average trade being worth of $1,530,854. The most recent stock trade was executed by William Benton Jones on 6 May 2024, trading 20,000 units of CRVS stock currently worth $34,600.

What does Corvus Pharmaceuticals Inc do?

corvus pharmaceuticals is a clinical-stage biopharmaceutical company focused on the development of novel, first-in-class agents that target the immune system to treat patients with cancer. with accomplished and talented scientists, and top-tier investors, we are well positioned in an exciting new era of immuno-oncology.

Corvus Pharmaceuticals Inc executives and stock owners

Corvus Pharmaceuticals Inc executives and other stock owners filed with the SEC include:

• Daniel Hunt,
  Senior Vice President, Chief Business Officer
• Mehrdad Mobasher,
  Vice President, Chief Medical Officer
• Richard Miller,
  Chairman of the Board, President, Chief Executive Officer
• Leiv Lea,
  Chief Financial Officer
• Dr. Mehrdad Mobasher M.D., M.P.H.,
  Sr. VP & Chief Medical Officer
• Leiv Lea,
  Chief Financial Officer
• Steve Krognes,
  Independent Director
• Peter Thompson,
  Independent Director
• Elisha Gould,
  Independent Director
• Dr. Richard A. Miller M.D.,
  Co-Founder, Pres, CEO & Chairman
• Scott Morrison,
  Independent Director
• Dr. Peter A. Thompson FACP, M.D.,
  Co-Founder & Independent Director
• Linda Grais,
  Independent Director
• Ian Clark,
  Independent Director
• Edith Mitchell,
  Director
• Erik Verner,
  Vice President of Chemistry Research
• William Jones,
  Senior Vice President of Pharmaceutical Development
• Dr. James T. Rosenbaum M.D.,
  Sr. VP of Research
• Dr. Erik J. Verner Ph.D.,
  Co-Founder
• Stephen Willingham,
  Sr. Scientist
• Alan C. Mendelson Esq.,
  Sec.
• Dr. Long Kwei Ph.D.,
  Sr. VP of Biometrics
• Dr. William Benton Jones,
  Sr. VP of Pharmaceutical Devel.
• Debra Horen SPHR,
  VP of HR
• Street Partners Llc Adams,
  10% owner
• Advisors Llc Orbi Med Capit...,
  
• Jason V Coloma,
  SVP, Chief Business Officer
• Holdings A/S Novo,
  10% owner
• Advisors Llc Orbimed,
  Director
• Terry P Gould,
  
• Joseph J Buggy,
  EVP, Discovery Research
• Advisors Llc Orbi Med Capit...,
  
• Capital, Llc Eco R1,
  10% owner
• Jeffrey Arcara,
  Chief Business Officer